4.5 Article

Using flash glucose monitoring in pregnancies in routine care of patients with gestational diabetes mellitus: a pilot study

期刊

ACTA DIABETOLOGICA
卷 60, 期 5, 页码 697-704

出版社

SPRINGER-VERLAG ITALIA SRL
DOI: 10.1007/s00592-023-02042-x

关键词

Gestational diabetes; Flash glucose monitoring; FGM; SMBG; Treatment; Perinatal outcome; Treatment satisfaction

向作者/读者索取更多资源

Flash glucose monitoring (FGM) has been approved for pregnant women with preexisting diabetes since 2017, but its use in gestational diabetes (GDM) has been a topic of debate. The lack of accuracy and recommended target values are the main concerns against using FGM in GDM. This pilot study analyzed the impact of FGM on pregnancy outcomes, patient satisfaction, and confirmed the safety of its use in GDM pregnancies.
AimFlash glucose monitoring (FGM) has been approved for the care of pregnant women with preexisting diabetes since 2017. However, its use in gestational diabetes (GDM) has been critically discussed. Inaccuracy and missing recommendations for target values are the main arguments against the use of FGM in GDM. To date, there is a lack of data to justify routine use of FGM in GDM pregnancies. Consequently, this new technology has been withheld from GDM-patients. Aim of our pilot study was to analyze the impact of FGM use on pregnancy outcomes, patient's satisfaction and to confirm the safe use in GDM pregnancies.MethodsCohort study of 37 FGM-managed GDM pregnancies compared with 74 matched women using self-monitoring of blood glucose (SMBG). Group comparison using nonparametric testing concerning patients characteristic and perinatal outcome focusing on adverse outcomes (preeclampsia, preterm delivery, large for gestational age, C-sections, neonatal intensive care unit admission, hyperbilirubinemia and hypoglycemia). Evaluation of patient's treatment satisfaction using the Diabetes Treatment Satisfaction Questionnaire change (DTSQc) and patient interviews.ResultsNo significant differences in patient's characteristics despite gestational age at diagnosis (FGM with 20 vs. SMBG with 25 weeks). No difference in gestational weight gain, HbA1c progression and perinatal outcome. Treatment satisfaction obtained by the DTSQc revealed a high level of satisfaction with FGM use.ConclusionFGM use was well accepted and did not affect perinatal outcome. Use of FGM during pregnancy is safe and non-inferior to the management with SBGM. FGM should be considered as an option in the management of GDM patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据